Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The epidermal growth factor receptor tyrosine kinase catalytic domain is a cytoplasmic region within the larger transmembrane receptor known as EGFR. This catalytic portion is responsible for transferring a phosphate group from ATP to specific tyrosine residues on target proteins—a process called phosphorylation. Ligand binding at the extracellular region induces dimerization of two receptors, which activates their intracellular kinases through autophosphorylation. The resulting signal cascade regulates key cellular processes such as proliferation, differentiation, and survival. Dysregulation or mutation in this region is strongly implicated in various cancers due to uncontrolled cell division.
Drugs targeting this molecule typically act as ATP competitors or allosteric inhibitors, blocking the transfer of a phosphate group from ATP to substrate proteins. This inhibits downstream signaling pathways responsible for cell proliferation and survival.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Epidermal growth factor receptor tyrosine kinase catalytic domain (EGFR TK domain).